The OSIR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OSIR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OSIR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OSIR Detailed Price Forecast - CNN Money||View OSIR Detailed Summary - Google Finance|
|View OSIR Detailed Summary - Yahoo! Finance||View OSIR Stock Research & Analysis - Zacks.com|
|View OSIR Trends & Analysis - Trade-Ideas||View OSIR Major Holders - Barrons|
|View OSIR Call Transcripts - NASDAQ||View OSIR Breaking News & Analysis - Seeking Alpha|
|View OSIR Annual Report - CompanySpotlight.com||View OSIR OTC Short Report - OTCShortReport.com|
|View OSIR Fundamentals - TradeKing||View OSIR SEC Filings - Bar Chart|
|View Historical Prices for OSIR - The WSJ||View Performance/Total Return for OSIR - Morningstar|
|View the Analyst Estimates for OSIR - MarketWatch||View the Earnings History for OSIR - CNBC|
|View the OSIR Earnings - StockMarketWatch||View OSIR Buy or Sell Recommendations - MacroAxis|
|View the OSIR Bullish Patterns - American Bulls||View OSIR Short Pain Metrics - ShortPainBot.com|
|View OSIR Stock Mentions - StockTwits||View OSIR Stock Mentions - PennyStockTweets|
|View OSIR Stock Mentions - Twitter||View OSIR Investment Forum News - Investor Hub|
|View OSIR Stock Mentions - Yahoo! Message Board||View OSIR Stock Mentions - Seeking Alpha|
|View Insider Transactions for OSIR - SECform4.com||View Insider Transactions for OSIR - Insider Cow|
|View OSIR Major Holdings Summary - CNBC||View Insider Disclosure for OSIR - OTC Markets|
|View Insider Transactions for OSIR - Yahoo! Finance||View Institutional Holdings for OSIR - NASDAQ|
|View OSIR Stock Insight & Charts - FinViz.com||View OSIR Investment Charts - StockCharts.com|
|View OSIR Stock Overview & Charts - BarChart||View OSIR User Generated Charts - Trading View|
The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares
Posted on Tuesday September 18, 2018
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...
Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
Posted on Monday September 17, 2018
COLUMBIA, Md., Sept. 17, 2018-- Osiris Therapeutics, Inc., a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that ...
The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic
Posted on Tuesday August 28, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial
Posted on Monday August 27, 2018
Dermagraft® (1) is a bioengineered human fibroblast-derived dermal substitute product that has been on the U.S. market for more than 15 years (2, 3). Grafix® is a cryopreserved placental tissue allograft that has been developed using a proprietary cryopreservation method. This method allows the retention of intact matrix, growth factors and cells native to placental tissue. Prior clinical studies have shown the safety and efficacy of both Grafix and Dermagraft when used in the treatment for chronic DFUs in their respective trials (4, 5). The study’s objective was to compare clinical outcomes and product cost between Grafix and Dermagraft as an adjunct to standard of care (SOC) in the treatment of chronic DFUs in a prospective, multicenter, single-blind study.